NanoPass

NanoPass Technologies LtdSeptember 8, 2015

NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune

NanoPass Technologies Ltd.May 6, 2015

 NanoPass Technologies Grants an Exclusive License to Circassia Pharmaceuticals, for use of its MicronJet600™ Device in Allergy Testing in the USNanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600™, its microneedle delivery device, to Circassia Pharmaceuticals plc.

NanoPass Technologies Ltd.May 13, 2013

NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine

NanoPass Technologies Ltd.April 9, 2013

IDRI and Medicago to present data at the World Vaccine Congress Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant
SEATTLE, WA, and QUEBEC CITY, QC, April 9, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in

NanoPass Technologies Ltd.November 28, 2012

NanoPass Technologies Grants a Commercial License to Janssen Pharmaceuticals, Inc., for use of its MicronJet Device
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for MicronJet®, its microneedle delivery device, with Janssen Pharmaceuticals, Inc. (JPI) for multiple vaccine fields.The license agreement will

NanoPass Technologies Ltd.July 30, 2012

NanoPass Secures Series B Investment to Accelerate Commercialization of its Intradermal Delivery Products
NanoPass Technologies Ltd., a pioneer in the development and commercialization of painless intradermal (skin) delivery solutions for vaccines and large molecules, announced today it has recently closed a new round of financing, led by Israel HealthCare Ventures (IHCV), a leading healthcare-dedicated venture capital